Description
The Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System’s Nuclear Medicine Service is planning to acquire two radiopharmaceutical therapies—Pluvicto (lutetium‑177 vipivotide tetraxetan) for advanced prostate cancer and Lutathera (lutetium‑177 dotatate) for neuroendocrine tumors. The VA intends to award a sole‑source delivery order to Novartis Pharmaceuticals Corporation under an existing contract (36F79720D0180) but is soliciting capability statements from other qualified manufacturers or authorized distributors who can provide the products on a Federal Supply Schedule. Respondents must be FDA‑certified, capable of supplying the specified quantities (116 units of Pluvicto and 13 units of Lutathera), and submit their statements by 10:00 a.m. PT on Thursday, November 1, 2026. The VA reserves the right to proceed without competition if no responses are received.
• Product: Pluvicto (116 doses) and Lutathera (13 doses) – radiopharmaceuticals for cancer therapy.
• Intended sole‑source contractor: Novartis Pharmaceuticals Corp. (NJ).
• Place of performance: VA Greater Los Angeles Healthcare System, Los Angeles, CA.
• Submission requirement: Capability statement, SAM UEI, business size/type, and any applicable GSA/FSS contract numbers.
• Deadline: 01 Nov 2026, 10:00 AM PT.
• No pricing, award, or performance period disclosed.
Attached files
Contact
Hestia Sim(Contracting Officer)